Abstract
Vitale et al. discuss the metabolic circuitries whereby tumor-associated macrophages condition their microenvironment to support the cancer growth, metastatic dissemination and resistance to treatment, and how such pathways can be therapeutically targeted.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 36-50 |
| Number of pages | 15 |
| Journal | Cell Metabolism |
| Volume | 30 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 2 2019 |
Keywords
- fatty acid oxidation
- glycolysis
- hypoxia
- immunosuppressive metabolites
- immunotherapy
- oxidative phosphorylation
ASJC Scopus subject areas
- Physiology
- Molecular Biology
- Cell Biology
Access to Document
Fingerprint Dive into the research topics of 'Macrophages and Metabolism in the Tumor Microenvironment'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Macrophages and Metabolism in the Tumor Microenvironment. / Vitale, Ilio; Manic, Gwenola; Coussens, Lisa M.; Kroemer, Guido; Galluzzi, Lorenzo.
In: Cell Metabolism, Vol. 30, No. 1, 02.07.2019, p. 36-50.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Macrophages and Metabolism in the Tumor Microenvironment
AU - Vitale, Ilio
AU - Manic, Gwenola
AU - Coussens, Lisa M.
AU - Kroemer, Guido
AU - Galluzzi, Lorenzo
N1 - Funding Information: I.V. is supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 2017, grant number 20417 ), Ministero Italiano della Salute (grant number RF_GR-2011-02351355 ), and a startup grant from the Italian Institute for Genomic Medicine (Turin, Italy). L.M.C. is supported by National Institutes of Health /National Cancer Institute, the Breast Cancer Research Foundation , and the Brenden-Colson Center for Pancreatic Health. G.K. is supported by the Ligue contre le Cancer (équipe labelisée); Agence National de la Recherche (ANR)—Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la Recherche sur le Cancer (ARC); Cancéropôle Ile-de-France ; Chancelerie des Universités de Paris (Legs Poix); Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour ; Institut National Du Cancer (INCa); Inserm (HTE); Institut Universitaire de France ; LeDucq Foundation ; the LabEx Immuno-Oncology ; the RHU Torino Lumière ; the Seerave Foundation ; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM). L.G. is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD); Breast Cancer Research Program (BRCP) (# BC180476P1 ); by a startup grant from the Department of Radiation Oncology at Weill Cornell Medicine (New York, US); by industrial collaborations with Lytix (Oslo, Norway) and Phosplatin (New York, US); and by donations from Phosplatin (New York, US), the Luke Heller TECPR2 Foundation (Boston, US), and Sotio a.s. (Prague, Czech Republic). Funding Information: I.V. is supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 2017, grant number 20417), Ministero Italiano della Salute (grant number RF_GR-2011-02351355), and a startup grant from the Italian Institute for Genomic Medicine (Turin, Italy). L.M.C. is supported by National Institutes of Health/National Cancer Institute, the Breast Cancer Research Foundation, and the Brenden-Colson Center for Pancreatic Health. G.K. is supported by the Ligue contre le Cancer (?quipe labelis?e); Agence National de la Recherche (ANR)?Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la Recherche sur le Cancer (ARC); Canc?rop?le Ile-de-France; Chancelerie des Universit?s de Paris (Legs Poix); Fondation pour la Recherche M?dicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; Institut National Du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumi?re; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM). L.G. is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD); Breast Cancer Research Program (BRCP) (#BC180476P1); by a startup grant from the Department of Radiation Oncology at Weill Cornell Medicine (New York, US); by industrial collaborations with Lytix (Oslo, Norway) and Phosplatin (New York, US); and by donations from Phosplatin (New York, US), the Luke Heller TECPR2 Foundation (Boston, US), and Sotio a.s. (Prague, Czech Republic). I.V. and L.G. conceived the paper and wrote the first version of the manuscript. G.M. prepared display items under the supervision of I.V. and L.G. L.M.C. and G.K. provided critical input to the preparation of the paper. I.V. and L.G. integrated comments from the reviewers. All authors approved the final version of the article. L.M.C. is a paid consultant for Cell Signaling Technologies, received reagent and/or research support from Plexxikon, Pharmacyclics, Acerta Pharma, Deciphera Pharmaceuticals, Genentech, Roche Glycart, Syndax Pharmaceuticals, and NanoString Technologies, and is member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, and Verseau Therapeutics. G.K. has been holding preclinical research contracts with Bayer Healthcare, Genentech, Glaxo Smyth Kline, Institut M?rieux, Lytix Pharma, PharmaMar, Sotio, and Vasculox, and he is on the Board of Directors of the Bristol Myers Squibb Foundation France, consults for Macrophage Pharma, and is a scientific co-founder of everImmune and Samsara Therapeutics. L.G. provides remunerated consulting to OmniSEQ, Astra Zeneca, VL47, and the Luke Heller TECPR2 Foundation, and he is a member of the Scientific Advisory Committee of OmniSEQ. All other authors have no relevant conflicts of interest to declare. Funding Information: I.V. is supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 2017, grant number 20417), Ministero Italiano della Salute (grant number RF_GR-2011-02351355), and a startup grant from the Italian Institute for Genomic Medicine (Turin, Italy). L.M.C. is supported by National Institutes of Health/National Cancer Institute, the Breast Cancer Research Foundation, and the Brenden-Colson Center for Pancreatic Health. G.K. is supported by the Ligue contre le Cancer (équipe labelisée); Agence National de la Recherche (ANR)—Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la Recherche sur le Cancer (ARC); Cancéropôle Ile-de-France; Chancelerie des Universités de Paris (Legs Poix); Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; Institut National Du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM). L.G. is supported by a Breakthrough Level 2 grant from the US Department of Defense (DoD); Breast Cancer Research Program (BRCP) (#BC180476P1); by a startup grant from the Department of Radiation Oncology at Weill Cornell Medicine (New York, US); by industrial collaborations with Lytix (Oslo, Norway) and Phosplatin (New York, US); and by donations from Phosplatin (New York, US), the Luke Heller TECPR2 Foundation (Boston, US), and Sotio a.s. (Prague, Czech Republic). I.V. and L.G. conceived the paper and wrote the first version of the manuscript. G.M. prepared display items under the supervision of I.V. and L.G. L.M.C. and G.K. provided critical input to the preparation of the paper. I.V. and L.G. integrated comments from the reviewers. All authors approved the final version of the article. L.M.C. is a paid consultant for Cell Signaling Technologies, received reagent and/or research support from Plexxikon, Pharmacyclics, Acerta Pharma, Deciphera Pharmaceuticals, Genentech, Roche Glycart, Syndax Pharmaceuticals, and NanoString Technologies, and is member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, and Verseau Therapeutics. G.K. has been holding preclinical research contracts with Bayer Healthcare, Genentech, Glaxo Smyth Kline, Institut Mérieux, Lytix Pharma, PharmaMar, Sotio, and Vasculox, and he is on the Board of Directors of the Bristol Myers Squibb Foundation France, consults for Macrophage Pharma, and is a scientific co-founder of everImmune and Samsara Therapeutics. L.G. provides remunerated consulting to OmniSEQ, Astra Zeneca, VL47, and the Luke Heller TECPR2 Foundation, and he is a member of the Scientific Advisory Committee of OmniSEQ. All other authors have no relevant conflicts of interest to declare.
PY - 2019/7/2
Y1 - 2019/7/2
N2 - Vitale et al. discuss the metabolic circuitries whereby tumor-associated macrophages condition their microenvironment to support the cancer growth, metastatic dissemination and resistance to treatment, and how such pathways can be therapeutically targeted.
AB - Vitale et al. discuss the metabolic circuitries whereby tumor-associated macrophages condition their microenvironment to support the cancer growth, metastatic dissemination and resistance to treatment, and how such pathways can be therapeutically targeted.
KW - fatty acid oxidation
KW - glycolysis
KW - hypoxia
KW - immunosuppressive metabolites
KW - immunotherapy
KW - oxidative phosphorylation
UR - http://www.scopus.com/inward/record.url?scp=85067206639&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067206639&partnerID=8YFLogxK
U2 - 10.1016/j.cmet.2019.06.001
DO - 10.1016/j.cmet.2019.06.001
M3 - Review article
AN - SCOPUS:85067206639
VL - 30
SP - 36
EP - 50
JO - Cell Metabolism
JF - Cell Metabolism
SN - 1550-4131
IS - 1
ER -